Molecular Targets for Diagnostics and Therapeutics of Severe Acute Respiratory Syndrome (SARS-CoV)
Identifieur interne : 000C18 ( Pmc/Curation ); précédent : 000C17; suivant : 000C19Molecular Targets for Diagnostics and Therapeutics of Severe Acute Respiratory Syndrome (SARS-CoV)
Auteurs : Pravin K. Bhatnagar ; Dipankar Das ; Mavanur R. SureshSource :
- Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques [ 1482-1826 ] ; 2008.
Abstract
The large number of deaths in a short period of time due to the spread of severe acute respiratory syndrome (SARS) infection led to the unparalleled collaborative efforts world wide to determine and characterize the new coronavirus (SARS-CoV). The full genome sequence was determined within weeks of the first outbreak by the Canadian group with international collaboration. As per the World Health Organization (WHO), the continual lack of a rapid laboratory test to aid the early diagnosis of suspected cases of SARS makes this area a priority for future research. To prevent deaths in the future, early diagnosis and therapy of this infectious disease is of paramount importance.
This review describes the specific molecular targets for diagnostics and therapeutics of viral infection.
The three major diagnostic methods available for SARS includes viral RNA detection by reverse transcription polymerase chain reaction (RT-PCR), virus induced antibodies by immunofluorescence assay (IFA) or by enzyme linked immunosorbant assay (ELISA) of nucleocapsid protein (NP). The spike glycoprotein of SARS-CoV is the major inducer of neutralizing antibodies. The receptor binding domain (RBD) in the S1 region of the spike glycoprotein contains multiple conformational epitopes that induces highly potent neutralizing antibodies. The genetically engineered attenuated form of the virus or viral vector vaccine encoding for the SARS-CoV spike glycoprotein has been shown to elicit protective immunity in vaccinated animals.
NP is the preferred target for routine detection of SARS-CoV infection by ELISA which is an economical method compared to other methods. The RBD of the spike glycoprotein is both a functional domain for cell receptor binding and also a major neutralizing determinant of SARS-CoV. The progress in evaluating a therapeutic or vaccine would depend on the availability of clinically relevant animal model.
Url:
PubMed: 19203466
PubMed Central: 2678938
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000C18
Links to Exploration step
PMC:2678938Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Molecular Targets for Diagnostics and Therapeutics of Severe Acute Respiratory Syndrome (SARS-CoV)</title>
<author><name sortKey="Bhatnagar, Pravin K" sort="Bhatnagar, Pravin K" uniqKey="Bhatnagar P" first="Pravin K." last="Bhatnagar">Pravin K. Bhatnagar</name>
</author>
<author><name sortKey="Das, Dipankar" sort="Das, Dipankar" uniqKey="Das D" first="Dipankar" last="Das">Dipankar Das</name>
</author>
<author><name sortKey="Suresh, Mavanur R" sort="Suresh, Mavanur R" uniqKey="Suresh M" first="Mavanur R." last="Suresh">Mavanur R. Suresh</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">19203466</idno>
<idno type="pmc">2678938</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2678938</idno>
<idno type="RBID">PMC:2678938</idno>
<date when="2008">2008</date>
<idno type="wicri:Area/Pmc/Corpus">000C18</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000C18</idno>
<idno type="wicri:Area/Pmc/Curation">000C18</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000C18</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Molecular Targets for Diagnostics and Therapeutics of Severe Acute Respiratory Syndrome (SARS-CoV)</title>
<author><name sortKey="Bhatnagar, Pravin K" sort="Bhatnagar, Pravin K" uniqKey="Bhatnagar P" first="Pravin K." last="Bhatnagar">Pravin K. Bhatnagar</name>
</author>
<author><name sortKey="Das, Dipankar" sort="Das, Dipankar" uniqKey="Das D" first="Dipankar" last="Das">Dipankar Das</name>
</author>
<author><name sortKey="Suresh, Mavanur R" sort="Suresh, Mavanur R" uniqKey="Suresh M" first="Mavanur R." last="Suresh">Mavanur R. Suresh</name>
</author>
</analytic>
<series><title level="j">Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques</title>
<idno type="eISSN">1482-1826</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="S1"><title>Purpose</title>
<p id="P1">The large number of deaths in a short period of time due to the spread of severe acute respiratory syndrome (SARS) infection led to the unparalleled collaborative efforts world wide to determine and characterize the new coronavirus (SARS-CoV). The full genome sequence was determined within weeks of the first outbreak by the Canadian group with international collaboration. As per the World Health Organization (WHO), the continual lack of a rapid laboratory test to aid the early diagnosis of suspected cases of SARS makes this area a priority for future research. To prevent deaths in the future, early diagnosis and therapy of this infectious disease is of paramount importance.</p>
</sec>
<sec sec-type="methods" id="S2"><title>Methods</title>
<p id="P2">This review describes the specific molecular targets for diagnostics and therapeutics of viral infection.</p>
</sec>
<sec id="S3"><title>Results</title>
<p id="P3">The three major diagnostic methods available for SARS includes viral RNA detection by reverse transcription polymerase chain reaction (RT-PCR), virus induced antibodies by immunofluorescence assay (IFA) or by enzyme linked immunosorbant assay (ELISA) of nucleocapsid protein (NP). The spike glycoprotein of SARS-CoV is the major inducer of neutralizing antibodies. The receptor binding domain (RBD) in the S1 region of the spike glycoprotein contains multiple conformational epitopes that induces highly potent neutralizing antibodies. The genetically engineered attenuated form of the virus or viral vector vaccine encoding for the SARS-CoV spike glycoprotein has been shown to elicit protective immunity in vaccinated animals.</p>
</sec>
<sec id="S4"><title>Conclusion</title>
<p id="P4">NP is the preferred target for routine detection of SARS-CoV infection by ELISA which is an economical method compared to other methods. The RBD of the spike glycoprotein is both a functional domain for cell receptor binding and also a major neutralizing determinant of SARS-CoV. The progress in evaluating a therapeutic or vaccine would depend on the availability of clinically relevant animal model.</p>
</sec>
</div>
</front>
</TEI>
<pmc article-type="research-article" xml:lang="EN"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">9807281</journal-id>
<journal-id journal-id-type="pubmed-jr-id">21788</journal-id>
<journal-id journal-id-type="nlm-ta">J Pharm Pharm Sci</journal-id>
<journal-title>Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques</journal-title>
<issn pub-type="epub">1482-1826</issn>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">19203466</article-id>
<article-id pub-id-type="pmc">2678938</article-id>
<article-id pub-id-type="manuscript">NIHMS102629</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Molecular Targets for Diagnostics and Therapeutics of Severe Acute Respiratory Syndrome (SARS-CoV)</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Bhatnagar</surname>
<given-names>Pravin K.</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Das</surname>
<given-names>Dipankar</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Suresh</surname>
<given-names>Mavanur R.</given-names>
</name>
</contrib>
<aff id="A1">Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada</aff>
</contrib-group>
<author-notes><corresp id="FN1">Corresponding Author: Dr. M.R. Suresh, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada, Email: <email>msuresh@pharmacy.ualberta.ca</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted"><day>18</day>
<month>3</month>
<year>2009</year>
</pub-date>
<pub-date pub-type="epub"><day>19</day>
<month>4</month>
<year>2008</year>
</pub-date>
<pub-date pub-type="pmc-release"><day>7</day>
<month>5</month>
<year>2009</year>
</pub-date>
<volume>11</volume>
<issue>2</issue>
<fpage>1s</fpage>
<lpage>13s</lpage>
<abstract><sec id="S1"><title>Purpose</title>
<p id="P1">The large number of deaths in a short period of time due to the spread of severe acute respiratory syndrome (SARS) infection led to the unparalleled collaborative efforts world wide to determine and characterize the new coronavirus (SARS-CoV). The full genome sequence was determined within weeks of the first outbreak by the Canadian group with international collaboration. As per the World Health Organization (WHO), the continual lack of a rapid laboratory test to aid the early diagnosis of suspected cases of SARS makes this area a priority for future research. To prevent deaths in the future, early diagnosis and therapy of this infectious disease is of paramount importance.</p>
</sec>
<sec sec-type="methods" id="S2"><title>Methods</title>
<p id="P2">This review describes the specific molecular targets for diagnostics and therapeutics of viral infection.</p>
</sec>
<sec id="S3"><title>Results</title>
<p id="P3">The three major diagnostic methods available for SARS includes viral RNA detection by reverse transcription polymerase chain reaction (RT-PCR), virus induced antibodies by immunofluorescence assay (IFA) or by enzyme linked immunosorbant assay (ELISA) of nucleocapsid protein (NP). The spike glycoprotein of SARS-CoV is the major inducer of neutralizing antibodies. The receptor binding domain (RBD) in the S1 region of the spike glycoprotein contains multiple conformational epitopes that induces highly potent neutralizing antibodies. The genetically engineered attenuated form of the virus or viral vector vaccine encoding for the SARS-CoV spike glycoprotein has been shown to elicit protective immunity in vaccinated animals.</p>
</sec>
<sec id="S4"><title>Conclusion</title>
<p id="P4">NP is the preferred target for routine detection of SARS-CoV infection by ELISA which is an economical method compared to other methods. The RBD of the spike glycoprotein is both a functional domain for cell receptor binding and also a major neutralizing determinant of SARS-CoV. The progress in evaluating a therapeutic or vaccine would depend on the availability of clinically relevant animal model.</p>
</sec>
</abstract>
<contract-num rid="AI1">U01 AI061233-02</contract-num>
<contract-sponsor id="AI1">National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID</contract-sponsor>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C18 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000C18 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Pmc |étape= Curation |type= RBID |clé= PMC:2678938 |texte= Molecular Targets for Diagnostics and Therapeutics of Severe Acute Respiratory Syndrome (SARS-CoV) }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:19203466" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |